APLS
Apellis Pharmaceuticals, Inc.
NASDAQ · Healthcare · Biotechnology · US
$41.03
+0.00%Year over year
Reported trailing growth
- Revenue
- +42.5%
- EBITDA
- +200.6%
- EBIT
- +188.7%
- EPS
- +159.2%
- Free cash flow
- +549.2%
- Operating cash flow
- +555.5%
Forward estimates
Based on analyst estimates
- Revenue
- —
- EBITDA
- —
- EPS
- —
Three-year CAGR
- Revenue
- +137.0%
- EBITDA
- +145.3%
- EBIT
- +133.6%
- Net income
- +111.3%
- EPS
- +111.3%
- Free cash flow
- +151.0%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Mar 1, 2026